In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Licensing Vivitrex: A Win for the Mid-sized Pharma and Specialists

Executive Summary

Cephalon's acquisition of US rights to Alkermes' Vivitrex, a long-acting formulation of the alcohol abuse drug naltrexone, is a clear sign that mid-sized companies with marketed products can--thanks to their significant cash flows--contend with Big Pharma for important specialist products.
Advertisement

Related Content

Reformulation has Ruled in Neurology Dealmaking--Until Now
The Rise of Regional Dealmaking
The Rise of Regional Dealmaking
Specialty Pharma: Eating Big Pharma's Lunch, Not Just its Leftovers?
Specialty Pharma: Eating Big Pharma's Lunch, Not Just its Leftovers?
Cephalon: Can Spec Pharma do R&D?
No Dilution Necessary: The Promise of Project Financing
Pfizer-Vicuron: Fill Pipeline, Minimize R&D Expense
Deal Statistics Quarterly, Q2 2005
Pfizer-Vicuron: Fill Pipeline, Minimize R&D Expense

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel